Salarius Pharma reports $2.4M preliminary cash; sells 141K shares for $493.5K

Decoy Therapeutics Inc.

Cash and cash equivalents estimated at $2.4M as of Dec 31, 2024 (preliminary, unaudited).
Issued 141,000 shares at $3.50/share to C/M Capital Master Fund LP for $493,500.
Also issued 1,410 commitment shares to the same investor.
Exemption from registration under Section 4(a)(2) and Regulation D claimed.
Sale followed written notice under Dec 12, 2024 Securities Purchase Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.